ASCO: Bristol Myers’ $800M Bispecific ADC Aces China Breast Cancer Study, Putting TROP2 Drugs on Notice

A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb licensed from SystImmune, in a $800M deal has shown strong phase 3 breast cancer results from China. The findings suggest the therapy as a potential competitor in the TROP2 treatment landscape while underscoring growing interest in next-generation ADCs.